AI highlights Public evidence, checked Sep 2026
Product Our proprietary technology combines hyperspectral analysis with artificial intelligence to classify embryos and oocytes based on their metabolic profiles. Describes its own product as AI on its own site: "artificial intelligence" Sep 2026 ↗ Product Multidimensional hyperspectral data powers our AI-based assessment tool unveiling information that goes beyond the human eye to deliver a robust evaluation of embryo and oocyte quality. Describes its own product as AI on its own site: "ai-based" Sep 2026 ↗ Product Discover how our AI-assisted metabolic imaging can make an impact through our portfolio of applications. Describes its own product as AI on its own site: "ai" Sep 2026 ↗